We announced our new literature-focused features in our last blog post. One of the unique features of our approach is that we use deep learning concepts, a subset of machine learning, to text mine literature. A characteristic of deep learning is that various characteristics, or attributes, of a ...

We are excited to announce improvements to BiomarkerBase, increasing the coverage and analysis of literature. We've added biomarkers sourced only from literature, representing biomarkers in an earlier stage of development.  With this addition there are two main benefits:

In a CotW a few weeks ago we postulated that based on biomarker discovery work Celgene is poised to dominate personalized medicine.  However, this week's chart suggests that if Celgene's rise in personalized medicine is to happen it could be a long ways off.  Other big pharma are getting biomarkers ...

A few months ago we investigated the use of unique biomarkers by big biopharma.  The use of unique biomarkers served as a measure of innovation for each of the biggest biopharma companies.  The most innovative companies are progressing biomarkers to trials more quickly than their less innovative ...

This week's chart is pulled from the same analysis we did last week.  Last week we introduced the concept of a biomarker quadrant showing Hot, Common, Emerging, and Under-performing biomarkers by usage since first introduced.  This week we want to simplify things  in our Chart of the Week.  This ...